Mario Paolo Colombo

Mario Paolo Colombo's AcademicInfluence.com Rankings

Mario Paolo Colombo

Computer Science

#5064

World Rank

#5350

Historical Rank

Computational Linguistics

#617

World Rank

#629

Historical Rank

Machine Learning

#1200

World Rank

#1220

Historical Rank

Artificial Intelligence

#1432

World Rank

#1461

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Mario Paolo Colombo's Degrees

PhD Computer Science ETH Zurich

Similar Degrees You Can Earn

Best Online PhD of Computer Science (Doctorates) 2026

Why Is Mario Paolo Colombo Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Mario Paolo Colombo's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards (2016) (1817)
Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. (2006) (863)
The terminology issue for myeloid-derived suppressor cells. (2007) (720)
Interleukin-12 in anti-tumor immunity and immunotherapy. (2002) (670)
Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo (1996) (597)
Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. (2005) (556)
IL-4-Induced Arginase 1 Suppresses Alloreactive T Cells in Tumor-Bearing Mice1 (2003) (533)
p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. (2006) (469)
The intriguing role of polymorphonuclear neutrophils in antitumor reactions. (2001) (437)
Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. (2005) (432)
OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection (2008) (387)
Regulatory T-cell inhibition versus depletion: the right choice in cancer immunotherapy (2007) (381)
Reversal of Tumor-induced Dendritic Cell Paralysis by CpG Immunostimulatory Oligonucleotide and Anti–Interleukin 10 Receptor Antibody (2002) (376)
CD4+CD25+ regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction. (2008) (374)
DNA Vaccination Against Rat Her-2/Neu p185 More Effectively Inhibits Carcinogenesis Than Transplantable Carcinomas in Transgenic BALB/c Mice1 2 (2000) (373)
Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. (2007) (364)
The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. (2008) (360)
Classification of current anticancer immunotherapies (2014) (357)
Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake. (1999) (352)
Interleukin 12–mediated Prevention of Spontaneous Mammary Adenocarcinomas in Two Lines of Her-2/neu Transgenic Mice (1998) (347)
Neutrophil extracellular traps mediate transfer of cytoplasmic neutrophil antigens to myeloid dendritic cells toward ANCA induction and associated autoimmunity. (2012) (334)
Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. (2003) (324)
Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. (2007) (317)
Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo (1991) (315)
Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. (2005) (297)
Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade (2018) (287)
Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. (2006) (281)
Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent. (2006) (268)
Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? (1994) (266)
Combined Allogeneic Tumor Cell Vaccination and Systemic Interleukin 12 Prevents Mammary Carcinogenesis in HER-2/neu Transgenic Mice (2001) (258)
Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes (1994) (257)
The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference * (2011) (245)
The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control. (1999) (221)
HOXB7 constitutively activates basic fibroblast growth factor in melanomas (1996) (218)
Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. (1992) (215)
Dendritic Cells Infiltrating Tumors Cotransduced with Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf) and Cd40 Ligand Genes Take up and Present Endogenous Tumor-Associated Antigens, and Prime Naive Mice for a Cytotoxic T Lymphocyte Response (1999) (215)
Amount of interleukin 12 available at the tumor site is critical for tumor regression. (1996) (207)
Matricellular proteins: from homeostasis to inflammation, cancer, and metastasis (2010) (204)
Mast cells counteract regulatory T-cell suppression through interleukin-6 and OX40/OX40L axis toward Th17-cell differentiation. (2009) (196)
Autoimmune skin inflammation is dependent on plasmacytoid dendritic cell activation by nucleic acids via TLR7 and TLR9 (2010) (194)
Gene transfer in dendritic cells, induced by oral DNA vaccination with Salmonella typhimurium, results in protective immunity against a murine fibrosarcoma. (1998) (193)
Cytokines, tumour-cell death and immunogenicity: a question of choice. (1997) (191)
Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. (1997) (185)
Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cell-produced interferon gamma (1993) (184)
Macrophage-derived SPARC bridges tumor cell-extracellular matrix interactions toward metastasis. (2008) (172)
IL-21 Induces Tumor Rejection by Specific CTL and IFN-γ-Dependent CXC Chemokines in Syngeneic Mice1 (2004) (170)
Immunizing and Curative Potential of Replicating and Nonreplicating Murine Mammary Adenocarcinoma Cells Engineered with Interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, Tumor Necrosis Factor α, Granulocyte-Macrophage Colony-stimulating Factor, and γ-Interferon Gene or Admixed with Conventional Adjuvants (1994) (168)
Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic interleukin 12. (1999) (159)
Cancer immunotherapy based on killing of Salmonella-infected tumor cells. (2005) (158)
IL-12 Inhibition of Endothelial Cell Functions and Angiogenesis Depends on Lymphocyte-Endothelial Cell Cross-Talk1 (2001) (155)
Nucleofection Is an Efficient Nonviral Transfection Technique for Human Bone Marrow–Derived Mesenchymal Stem Cells (2006) (152)
CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis. (2010) (149)
HOXB7: a key factor for tumor-associated angiogenic switch. (2001) (148)
Wild-type HFE protein normalizes transferrin iron accumulation in macrophages from subjects with hereditary hemochromatosis. (2000) (145)
RORC1 Regulates Tumor-Promoting "Emergency" Granulo-Monocytopoiesis. (2015) (144)
Leukocyte, Rather than Tumor-produced SPARC, Determines Stroma and Collagen Type IV Deposition in Mammary Carcinoma (2003) (143)
An efficient Th2-type memory follows CD8+ lymphocyte-driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4. (1994) (140)
CD4 T cells inhibit in vivo the CD8‐mediated immune response against murine colon carcinoma cells transduced with interleukin‐12 genes (1995) (137)
Single Cell Sequencing of Mouse Heart Immune Infiltrate in Pressure Overload-Driven Heart Failure Reveals Extent of Immune Activation. (2019) (137)
Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma. (2006) (137)
TNF-Related Apoptosis-Inducing Ligand (TRAIL)–Armed Exosomes Deliver Proapoptotic Signals to Tumor Site (2016) (136)
Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. (2003) (136)
Lipopolysaccharide or Whole Bacteria Block the Conversion of Inflammatory Monocytes into Dendritic Cells In Vivo (2003) (134)
Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death. (2010) (129)
Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors (2019) (129)
CD40/CD40L interaction regulates CD4+CD25+ T reg homeostasis through dendritic cell‐produced IL‐2 (2005) (122)
Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers. (2011) (122)
Consensus nomenclature for CD8+ T cell phenotypes in cancer (2015) (118)
Cell therapy: achievements and perspectives. (1999) (116)
The P2X7 receptor modulates immune cells infiltration, ectonucleotidases expression and extracellular ATP levels in the tumor microenvironment (2019) (113)
Inhibiting interactions of lysine demethylase LSD1 with snail/slug blocks cancer cell invasion. (2013) (112)
Molecular mechanisms of CD99-induced caspase-independent cell death and cell–cell adhesion in Ewing's sarcoma cells: actin and zyxin as key intracellular mediators (2004) (112)
Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out. (2019) (111)
Targeting myelomonocytic cells to revert inflammation-dependent cancer promotion. (2005) (108)
Lack of Il12rb2 signaling predisposes to spontaneous autoimmunity and malignancy. (2005) (106)
In Ewing's sarcoma CCN3(NOV) inhibits proliferation while promoting migration and invasion of the same cell type (2005) (104)
Expression of cytokine genes, including IL‐6, in human malignant melanoma cell lines (1992) (100)
Bone marrow stroma in humans: anti-nerve growth factor receptor antibodies selectively stain reticular cells in vivo and in vitro (1993) (100)
CD25+ Regulatory T Cell Depletion Augments Immunotherapy of Micrometastases by an IL-21-Secreting Cellular Vaccine1 (2006) (99)
Interleukin 12 potentiates the curative effect of a vaccine based on interleukin 2-transduced tumor cells. (1996) (98)
Osteopontin shapes immunosuppression in the metastatic niche. (2014) (98)
Identification of a novel interleukin-15 (IL-15) transcript isoform generated by alternative splicing in human small cell lung cancer cell lines. (1996) (97)
Defective stromal remodeling and neutrophil extracellular traps in lymphoid tissues favor the transition from autoimmunity to lymphoma. (2014) (95)
Transduction of the SkBr3 breast carcinoma cell line with the HOXB7 gene induces bFGF expression, increases cell proliferation and reduces growth factor dependence (1998) (94)
Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing. (1998) (91)
Antitumor vaccination: where we stand. (2000) (91)
Caveolin-1 reduces osteosarcoma metastases by inhibiting c-Src activity and met signaling. (2007) (89)
Granulocyte colony-stimulating factor (G-CSF) gene transduction in murine adenocarcinoma drives neutrophil-mediated tumor inhibition in vivo. Neutrophils discriminate between G-CSF-producing and G-CSF-nonproducing tumor cells. (1992) (88)
Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells. (1996) (87)
Immunoprevention of cancer: is the time ripe? (2000) (87)
Triggering CD40 on endothelial cells contributes to tumor growth (2006) (85)
Suppression of Invasion and Metastasis of Triple-Negative Breast Cancer Lines by Pharmacological or Genetic Inhibition of Slug Activity123 (2014) (79)
Mast cells and Th17 cells contribute to the lymphoma-associated pro-inflammatory microenvironment of angioimmunoblastic T-cell lymphoma. (2010) (77)
In vitro anti‐tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2. Role of interleukin 5 (1993) (77)
Inhibition of proliferation by c-myb antisense oligodeoxynucleotides in colon adenocarcinoma cell lines that express c-myb. (1991) (76)
Mesenchymal Transition of High-Grade Breast Carcinomas Depends on Extracellular Matrix Control of Myeloid Suppressor Cell Activity. (2016) (76)
Interleukin-12 as an adjuvant for cancer immunotherapy. (1999) (74)
Tumor-intrinsic and -extrinsic roles of c-Kit: mast cells as the primary off-target of tyrosine kinase inhibitors (2011) (74)
IL-15 cis presentation is required for optimal NK cell activation in lipopolysaccharide-mediated inflammatory conditions. (2013) (74)
Immunotherapy of experimental metastases by vaccination with interleukin gene-transduced adenocarcinoma cells sharing tumor-associated antigens. Comparison between IL-12 and IL-2 gene-transduced tumor cell vaccines. (1996) (74)
Enhanced Efficacy of Tumor Cell Vaccines Transfected with Secretable hsp70 (2004) (73)
The Aryl Hydrocarbon Receptor Modulates Acute and Late Mast Cell Responses (2012) (71)
Limited efficacy of the HSV-TK/GCV system for gene therapy of malignant gliomas and perspectives for the combined transduction of the interleukin-4 gene. (1997) (71)
Multiple molecular alterations in mouse lung tumors (1992) (71)
Hepatitis C: The beginning of the end—key elements for successful European and national strategies to eliminate HCV in Europe (2018) (70)
Eradication of rat malignant gliomas by retroviral-mediated, in vivo delivery of the interleukin 4 gene. (1999) (70)
OX40 Ligand-Transduced Tumor Cell Vaccine Synergizes with GM-CSF and Requires CD40-Apc Signaling to Boost the Host T Cell Antitumor Response1 (2003) (69)
Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody. (1998) (69)
A non‐redundant role for OX40 in the competitive fitness of Treg in response to IL‐2 (2010) (68)
CD99 acts as an oncosuppressor in osteosarcoma. (2006) (68)
Enforced expression of HOXB7 promotes hematopoietic stem cell proliferation and myeloid-restricted progenitor differentiation (1999) (68)
Bone marrow stroma in humans: anti-nerve growth factor receptor antibodies selectively stain reticular cells in vivo and in vitro. (1993) (67)
Interleukin 12 gene therapy of MHC-negative murine melanoma metastases. (1998) (65)
SPARC oppositely regulates inflammation and fibrosis in bleomycin-induced lung damage. (2011) (65)
Role of PLZF in melanoma progression (2004) (64)
Interferon γ–independent Rejection of Interleukin 12–transduced Carcinoma Cells Requires CD4+ T Cells and Granulocyte/Macrophage Colony–stimulating Factor (1998) (64)
The Role of Mast Cells in Molding the Tumor Microenvironment (2015) (64)
IL-12 inhibits apoptosis induced in a human Th1 clone by gp120/CD4 cross-linking and CD3/TCR activation or by IL-2 deprivation. (1995) (64)
Paracrine delivery of IL-12 against intracranial 9L gliosarcoma in rats. (2000) (63)
Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells. (1999) (62)
Accelerated dendritic-cell migration and T-cell priming in SPARC-deficient mice (2005) (61)
Modulation of multidrug resistance by verapamil or mdr1 anti‐sense oligodeoxynucleotide does not change the high susceptibility to lymphokine‐activated killers in mdr‐resistant human carcinoma (LoVo) line (1990) (61)
ATP Release from Chemotherapy-Treated Dying Leukemia Cells Elicits an Immune Suppressive Effect by Increasing Regulatory T Cells and Tolerogenic Dendritic Cells (2017) (61)
Exacerbated experimental autoimmune encephalomyelitis in mast-cell-deficient KitW-sh/W-sh mice (2011) (60)
In vivo correction of genetic defects of monocyte/ macrophages using attenuated Salmonella as oral vectors for targeted gene delivery (2000) (60)
Mast Cells Boost Myeloid-Derived Suppressor Cell Activity and Contribute to the Development of Tumor-Favoring Microenvironment (2014) (60)
Tumor-Derived Prostaglandin E2 Promotes p50 NF-κB-Dependent Differentiation of Monocytic MDSCs (2020) (59)
Rheostatic Functions of Mast Cells in the Control of Innate and Adaptive Immune Responses. (2017) (58)
IL-4-transduced tumor cell vaccine induces immunoregulatory type 2 CD8 T lymphocytes that cure lung metastases upon adoptive transfer. (1999) (58)
Salmonella vaccine carrier strains: effective delivery system to trigger anti‐tumor immunity by oral route (1999) (58)
Feasibility and reproducibility of spleen transient elastography and its role in combination with liver transient elastography for predicting the severity of chronic viral hepatitis (2014) (57)
The abrogation of the HOXB7/PBX2 complex induces apoptosis in melanoma through the miR-221&222-c-FOS pathway (2013) (56)
c-fes expression in ontogenetic development and hematopoietic differentiation. (1994) (56)
The induction of in vivo proliferation of long-lived CD44hi CD8+ T cells after the injection of tumor cells expressing IFN-alpha1 into syngeneic mice. (1998) (56)
Interleukin-6 expression in human neutrophil and eosinophil peripheral blood granulocytes (1993) (56)
Mast cells, basophils and eosinophils: From allergy to cancer. (2018) (55)
A B7‐1‐transfected human melanoma line stimulates proliferation and cytotoxicity of autologous and allogeneic lymphocytes (1995) (54)
Cytokine gene transduction in the immunotherapy of cancer. (1997) (54)
Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C (2013) (53)
The dark side of mast cell-targeted therapy in prostate cancer. (2012) (53)
Neoplastic and Stromal Cells Contribute to an Extracellular Matrix Gene Expression Profile Defining a Breast Cancer Subtype Likely to Progress (2013) (53)
The defined attenuated Listeria monocytogenes Δmpl2 mutant is an effective oral vaccine carrier to trigger a long‐lasting immune response against a mouse fibrosarcoma (1997) (53)
The bone marrow stroma in hematological neoplasms—a guilty bystander (2011) (52)
Smac mimetics induce inflammation and necrotic tumour cell death by modulating macrophage activity (2013) (52)
Differential susceptibility to HIV-GP120-sensitized apoptosis in CD4+ T-cell clones with different T-helper phenotypes: role of CD95/CD95L interactions. (1997) (51)
IgG2a induced by interleukin (IL) 12-producing tumor cell vaccines but not IgG1 induced by IL-4 vaccine is associated with the eradication of experimental metastases. (1998) (51)
The high lysability by lak cells of colon‐carcinoma cells resistant to doxorubicin is associated with a high expression of ICAM‐1, LFA‐3, NCA and a less‐differentiated phenotype (1991) (51)
Stromal SPARC contributes to the detrimental fibrotic changes associated with myeloproliferation whereas its deficiency favors myeloid cell expansion. (2012) (50)
Genetic modification of a carcinoma with the IL‐4 gene increases the influx of dendritic cells relative to other cytokines (1997) (49)
Trabectedin Overrides Osteosarcoma Differentiative Block and Reprograms the Tumor Immune Environment Enabling Effective Combination with Immune Checkpoint Inhibitors (2017) (49)
Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gamma-interferon gene or admixed with conventional a (1994) (48)
Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer. (2019) (48)
Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer (2021) (48)
Redundancy of autocrine loops in human rhabdomyosarcoma cells: induction of differentiation by suramin. (1995) (47)
Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: evaluation of efficacy and tolerability (1997) (47)
Vaccination of Stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells (2002) (47)
Sarcoma Eradication by Doxorubicin and Targeted TNF Relies upon CD8+ T-cell Recognition of a Retroviral Antigen. (2017) (46)
Antitumor effect of interleukin (IL)-12 in the absence of endogenous IFN-gamma: a role for intrinsic tumor immunogenicity and IL-15. (2002) (45)
IFN‐γ‐independent synergistic effects of IL‐12 and IL‐15 induce anti‐tumor immune responses in syngeneic mice (2002) (45)
Nicotinamide Phosphoribosyltransferase Acts as a Metabolic Gate for Mobilization of Myeloid-Derived Suppressor Cells. (2019) (45)
Interleukin-2 gene-transduced human melanoma cells efficiently stimulate MHC-unrestricted and MHC-restricted autologous lymphocytes. (1994) (44)
Chaperon and adjuvant activity of hsp70: different natural killer requirement for cross-priming of chaperoned and bystander antigens. (2005) (44)
Peripheral regulatory T cells and serum transforming growth factor‐&bgr;: Relationship with clinical response to infliximab in Crohn's disease (2010) (44)
Bone marrow stroma CD40 expression correlates with inflammatory mast cell infiltration and disease progression in splenic marginal zone lymphoma. (2014) (44)
Constitutive activation of the ETS-1-miR-222 circuitry in metastatic melanoma (2011) (43)
CD99 regulates neural differentiation of Ewing sarcoma cells through miR-34a-Notch-mediated control of NF-κB signaling (2016) (42)
Intratumor OX40 stimulation inhibits IRF1 expression and IL‐10 production by Treg cells while enhancing CD40L expression by effector memory T cells (2011) (41)
Cross-Talk between Myeloid-Derived Suppressor Cells and Mast Cells Mediates Tumor-Specific Immunosuppression in Prostate Cancer (2018) (40)
Cytokine-induced tumor immunogenicity: from exogenous cytokines to gene therapy. (1993) (39)
Liver stiffness measurement reliability and main determinants of point shear‐wave elastography in patients with chronic liver disease (2016) (39)
Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin (2012) (39)
Evaluation of osteonectin as a diagnostic marker of osteogenic bone tumors. (1992) (38)
Matricellular proteins at the crossroad of inflammation and cancer. (2008) (38)
IMPAIRED H‐2 EXPRESSION IN B 16 MELANOMA VARIANTS (1983) (37)
An in vivo model to compare human leukocyte infiltration in carcinoma xenografts producing different chemokines (1995) (37)
In vivo manipulation of dendritic cell migration and activation to elicit antitumour immunity. (2004) (37)
IL‐1α gene‐transfected human melanoma cells increase tumor‐cell adhesion to endothelial cells and their retention in the lung of nude mice (1996) (37)
Oncogene-driven intrinsic inflammation induces leukocyte production of tumor necrosis factor that critically contributes to mammary carcinogenesis. (2010) (36)
CD99 Triggering in Ewing Sarcoma Delivers a Lethal Signal through p53 Pathway Reactivation and Cooperates with Doxorubicin (2014) (35)
SOCS2 Controls Proliferation and Stemness of Hematopoietic Cells under Stress Conditions and Its Deregulation Marks Unfavorable Acute Leukemias. (2015) (35)
CD99 Drives Terminal Differentiation of Osteosarcoma Cells by Acting as a Spatial Regulator of ERK 1/2† (2013) (35)
Absence of the CD1 Molecule Up-Regulates Antitumor Activity Induced by CpG Oligodeoxynucleotides in Mice1 (2002) (35)
Diagnostic role of circulating extracellular matrix-related proteins in non-small cell lung cancer (2018) (35)
Interleukin-6 expression in human neutrophil and eosinophil peripheral blood granulocytes. (1993) (35)
B7.1 gene transduction of human renal‐cell‐carcinoma cell lines restores the proliferative response and cytotoxic function of allogeneic T cells (1996) (34)
CD99 triggering induces methuosis of Ewing sarcoma cells through IGF-1R/RAS/Rac1 signaling (2016) (34)
Intralesional Injection of Adenovirus Encoding CC Chemokine Ligand 16 Inhibits Mammary Tumor Growth and Prevents Metastatic-Induced Death after Surgical Removal of the Treated Primary Tumor1 (2004) (34)
SPARC Is a New Myeloid-Derived Suppressor Cell Marker Licensing Suppressive Activities (2019) (34)
Stromal niche communalities underscore the contribution of the matricellular protein SPARC to B-cell development and lymphoid malignancies (2014) (33)
Mast Cells in the Pathogenesis of Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis (2012) (32)
Mast Cells Control the Expansion and Differentiation of IL-10–Competent B Cells (2014) (32)
Response of a comprehensive cancer center to the COVID-19 pandemic: the experience of the Fondazione IRCCS–Istituto Nazionale dei Tumori di Milano (2020) (32)
In vitro detection of cell‐mediated immunity to individual tumor‐specific antigens of chemically induced BALB/c fibrosarcomas (1983) (32)
Human melanoma cells express a functional interleukin‐2 receptor (1993) (31)
Different requirements for α‐galactosylceramide and recombinant IL‐12 antitumor activity in the treatment of C‐26 colon carcinoma hepatic metastases (2001) (31)
Overexpression of protectin (CD59) down‐modulates the susceptibility of human melanoma cells to homologous complement (2000) (31)
Active immunization of metastatic melanoma patients with interleukin-4 transduced, allogeneic melanoma cells. A phase I-II study. (1994) (31)
Interleukin-12 production by leukemia-derived dendritic cells counteracts the inhibitory effect of leukemic microenvironment on T cells. (2005) (31)
SCD5‐induced oleic acid production reduces melanoma malignancy by intracellular retention of SPARC and cathepsin B (2015) (31)
Modulation of host immune responses stimulated by Salmonella vaccine carrier strains by using different promoters to drive the expression of the recombinant antigen (2000) (30)
The matricellular protein SPARC supports follicular dendritic cell networking toward Th17 responses. (2011) (30)
Somatic gene therapy of human melanoma: preclinical studies and early clinical trials. (1995) (29)
Common extracellular matrix regulation of myeloid cell activity in the bone marrow and tumor microenvironments (2017) (29)
Reconstitution of human telomerase reverse transcriptase expression rescues colorectal carcinoma cells from in vitro senescence: evidence against immortality as a constitutive trait of tumor cells. (2005) (29)
Down-regulation of interleukin 6 receptor alpha chain in interleukin 6 transduced melanoma cells causes selective resistance to interleukin 6 but not to oncostatin M. (1995) (29)
Endogenous retroviruses lead to the expression of a histocompatibility antigen detectable by skin graft rejection. (1987) (29)
Hepatitis C virus genotype 1b and risk of hepatocellular carcinoma (1997) (29)
Immunodominance in the T cell response to multiple non-H-2 histocompatibility antigens. IV. Partial tissue distribution and mapping of immunodominant antigens. (1987) (29)
Hepatitis C in haemophilia: lights and shadows (2004) (28)
Treatment of primary sclerosing cholangitis with low-dose ursodeoxycholic acid: results of a retrospective Italian multicentre survey. (2003) (26)
The good and bad of targeting cancer-associated extracellular matrix. (2017) (26)
755 5-YEAR ENTECAVIR TREATMENT IN NUC-NAÏVE, FIELD-PRACTICE PATIENTS WITH CHRONIC HEPATITIS B SHOWED EXCELLENT VIRAL SUPPRESSION AND SAFETY PROFILE BUT NO PREVENTION OF HCC IN CIRRHOTICS (2013) (26)
Modulation of FcεRI-dependent mast cell response by OX40L via Fyn, PI3K, and RhoA. (2012) (25)
Immunotherapy I: Cyclosine gene transfer strategies (1996) (25)
Cross‐reactions between tumor cells and allogeneic normal tissues. inhibition of a syngeneic lymphoma outgrowth in h‐2 and non‐h‐2 alloimmune balb/c mice (1982) (25)
Immune Checkpoint Ligand Reverse Signaling: Looking Back to Go Forward in Cancer Therapy (2019) (25)
Convergences and Divergences of Thymus- and Peripherally Derived Regulatory T Cells in Cancer (2013) (25)
Recovery after L-DOPA treatment in peginterferon and ribavirin induced parkinsonism. (2008) (24)
Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: evaluation of efficacy and tolerability (1997) (24)
Cytotoxic T lymphocyte response against non-immunoselected tumor antigens predicts the outcome of gene therapy with IL-12-transduced tumor cell vaccine (1999) (24)
Autologous and MHC class I-negative allogeneic tumor cells secreting IL-12 together cure disseminated A20 lymphoma. (2003) (24)
Persistent Immune Stimulation Exacerbates Genetically Driven Myeloproliferative Disorders via Stromal Remodeling. (2017) (23)
Hypoxic tumor cell death and modulation of endothelial adhesion molecules in the regression of granulocyte colony-stimulating factor-transduced tumors. (1996) (23)
Regulated Expression of miR-155 is Required for iNKT Cell Development (2015) (23)
Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial. (2019) (22)
Mast Cells Infiltrating Inflamed or Transformed Gut Alternatively Sustain Mucosal Healing or Tumor Growth. (2015) (22)
HOXB7 expression is regulated by the transcription factors NF-Y, YY1, Sp1 and USF-1. (2003) (22)
DNA threads released by activated CD4+ T lymphocytes provide autocrine costimulation (2019) (22)
Contrasting roles of SPARC-related granuloma in bacterial containment and in the induction of anti–Salmonella typhimurium immunity (2008) (22)
Polyps wrap mast cells and Treg within tumorigenic tentacles. (2009) (21)
Angiopoietin decoy secreted at tumor site impairs tumor growth and metastases by inducing local inflammation and altering neoangiogenesis (2004) (21)
Xg expression in Ewing's sarcoma is of prognostic value and contributes to tumor invasiveness. (2010) (21)
Immunometabolic Status of COVID-19 Cancer Patients (2020) (20)
Ledipasvir/Sofosbuvir for 12 or 24 Weeks Is Safe and Effective in Kidney Transplant Recipients with Chronic Genotype 1 or 4 Hcv Infection (2016) (20)
Simultaneous transduction of B7-1 and IL-2 genes into human melanoma cells to be used as vaccine: enhancement of stimulatory activity for autologous and allogeneic lymphocytes (2001) (19)
IL-1alpha gene-transfected human melanoma cells increase tumor-cell adhesion to endothelial cells and their retention in the lung of nude mice. (1996) (19)
Sustained suppression of hepatitis C virus by high doses of interferon and ribavirin in adult hemophilic patients (2004) (19)
85 Five years of sequential LAM TO LAM+ADV therapy suppresses HBV replication in most HBeAg-negative cirrhotics, preventing decompensation but not hepatocellular carcinoma (2006) (19)
Cytokine-based gene therapy of human tumors. An overview. (1996) (19)
98 EXTENDED (2 YEARS) TREATMENT WITH PEGINTERFERON ALFA-2A [40KD] IMPROVES SUSTAINED RESPONSE RATES IN GENOTYPE D PATIENTS WITH HBEAG NEGATIVE CHRONIC HEPATITIS B (2010) (18)
Expression levels of insulin receptor substrate-1 modulate the osteoblastic differentiation of mesenchymal stem cells and osteosarcoma cells (2014) (18)
Proliferating cell nuclear antigen assessed by a computer-assisted image analysis system in patients with chronic viral hepatitis and cirrhosis. (2002) (18)
Cytokine gene transduction in tumor cells: interleukin (IL)-2 or IL-4 gene transfer in human melanoma cells. (1994) (18)
Anti‐tumor activity of CpG‐ODN aerosol in mouse lung metastases (2013) (18)
Interaction between endothelial cells and the secreted cytokine drives the fate of an IL4‐ or an IL5‐transduced tumour (1998) (18)
Localization of growth arrest-specific genes on mouse Chromosomes 1, 7, 8, 11, 13, and 16 (2004) (17)
The evolutionarily conserved long non‐coding RNA LINC00261 drives neuroendocrine prostate cancer proliferation and metastasis via distinct nuclear and cytoplasmic mechanisms (2021) (17)
A Spatially Resolved Dark- versus Light-Zone Microenvironment Signature Subdivides Germinal Center-Related Aggressive B Cell Lymphomas (2020) (17)
Infiltrating Mast Cell–Mediated Stimulation of Estrogen Receptor Activity in Breast Cancer Cells Promotes the Luminal Phenotype (2020) (16)
cIAP1 regulates the EGFR/Snai2 axis in triple-negative breast cancer cells (2018) (16)
Matricellular proteins tune myeloid‐derived suppressor cell recruitment and function in breast cancer (2017) (16)
Intra-tumour heterogeneity of diffuse large B-cell lymphoma involves the induction of diversified stroma-tumour interfaces (2020) (16)
6576 POSTER Phase II Safety Study of the Oral Multikinase Inhibitor Regorafenib (BAY 73-4506) as Second-line Therapy in Patients With Hepatocellular Carcinoma (2011) (16)
OC7 AN IL28B POLYMORPHISM PREDICTS PEGYLATED INTERFERON PLUS RIBAVIRIN TREATMENT OUTCOME IN CHRONIC HEPATITIS C GENOTYPE 4 (2011) (16)
Apoptosis induced by HIV‐gp120 in a Th1 clone involves the generation of reactive oxygen intermediates downstream CD95 triggering (1997) (15)
A luminal EF-hand mutation in STIM1 in mice causes the clinical hallmarks of tubular aggregate myopathy (2019) (15)
Passive adoptive immunotherapy of low‐immunogenic BALB/C lymphoma by syngeneic alloimmune T lymphocytes (1984) (15)
Microenvironment-Centred Dynamics in Aggressive B-Cell Lymphomas (2012) (15)
DNA vaccination against the ovarian carcinoma-associated antigen folate receptor α (FRα) induces cytotoxic T lymphocyte and antibody responses in mice (1999) (15)
Immunotherapy I: Cytokine gene transfer strategies (2004) (14)
IL‐10‐producing B cells are characterized by a specific methylation signature (2019) (13)
A human melanoma cell line transduced with an interleukin-4 gene by a retroviral vector releases biologically active IL-4 and maintains the original tumor antigenic phenotype. (1995) (13)
Cooperative effects of Mycobacterium tuberculosis Ag38 gene transduction and interleukin 12 in vaccination against spontaneous tumor development in proto-neu transgenic mice. (2000) (13)
HOXB 7 : A Key Factor for Tumor-associated Angiogenic Switch 1 (2001) (13)
Nature and potential of the reactive response to mouse mammary adenocarcinoma cells engineered with interleukin-2, interleukin-4 or interferon-gamma genes. (1994) (13)
Down-regulation of SPARC/osteonectin/BM-40 expression in methylcholanthrene-induced fibrosarcomas and in Kirsten-MSV transformed fibroblasts. (1991) (13)
MicroRNA-221/-222 pathway controls melanoma progression (2008) (13)
IL-4 gene transfer for the treatment of experimental gliomas. (1998) (12)
Hepatitis C virus/human immunodeficiency virus coinfection in hemophiliacs: high rates of sustained virologic response to pegylated interferon and ribavirin therapy (2009) (12)
Lymphotoxin gene expression by melanocytes and melanoma cell lines and persistence of unspliced mRNA (1993) (12)
Active immunization of metastatic melanoma patients with IL-2 or IL-4 gene transfected, allogeneic melanoma cells. (1998) (12)
Liver Follicular Helper T-Cells Predict the Achievement of Virological Response following Interferon-Based Treatment in HCV-Infected Patients (2012) (12)
ORAL COMMUNICATIONSOC.07.1 2-YEAR EFFECTIVENESS AND SAFETY OF TENOFOVIR IN 302 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B: A MULTICENTER EUROPEAN STUDY IN CLINICAL PRACTICE (2012) (12)
Different tumours, transduced with different cytokine genes as G-CSF and IL-2, show inhibition of tumour take through neutrophil activation but differ in T cell functions. (1994) (12)
Choosing the Best Chemotherapy Agent to Boost Immune Checkpoint Inhibition Activity. (2018) (11)
930 HIGH RISK OF RENAL IMPAIRMENT DURING LONG-TERM ADEFOVIR AND LAMIVUDINE COMBINATION THERAPY IN PATIENTS WITH LAMIVUDINE-RESISTANT CHRONIC HEPATITIS B (2009) (11)
Erratum: In vitro anti-tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2. Role of interleukin 5 (Int. J. Cancer, 54, 8-15 (1993)) (1993) (11)
Genetic deletion of osteopontin in TRAMP mice skews prostate carcinogenesis from adenocarcinoma to aggressive human-like neuroendocrine cancers (2015) (11)
Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment (2019) (11)
In vivo reexpression of H-2 antigens in B16 melanoma cells. (1985) (11)
742TiPPHASE 3 RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY OF CABOZANTINIB (XL184) VS PLACEBO IN SUBJECTS WITH HEPATOCELLULAR CARCINOMA WHO HAVE RECEIVED PRIOR SORAFENIB (CELESTIAL) (NCT01908426). (2014) (11)
Five years of sequential lam to lam_adv therapy suppresses HBV replication in most hbeag-negative cirrhotics, preventing decompensation but not hepatocellular carcinoma (2005) (11)
T Cell Costimulation Blockade Blunts Age-Related Heart Failure (2020) (11)
Isolation and mapping to 17p12-13 of the human homologous of the murine growth arrest specific Gas-3 gene. (1992) (11)
829 EFFECTIVENESS OF HEPATITIS C VIRUS TREATMENT IN REAL-LIFE PRACTICE: A PROSPECTIVE OBSERVATIONAL MULTICENTER STUDY IN ITALY (PROBE) (2008) (10)
522 MAINTAINED VIRAL SUPPRESSION AND EXCELLENT SAFETY PROFILE OF ENTECAVIR MONOTHERAPY IN 418 NUC-NAÏVE PATIENTS WITH CHRONIC HEPATITIS B: A 4-YEAR FIELD PRACTICE, MULTICENTER STUDY (2012) (10)
C-EDGE IBLD: Efficacy and Safety of Elbasvir/Grazoprevir (EBR/GZR) in Subjects with Chronic Hepatitis C Virus Infection and Inherited Blood Disorders (2016) (10)
HIV/gp120 and PMA/ionomycin induced apoptosis but not activation induced cell death require PKC for Fas‐L upregulation (1998) (10)
Separation of Dual Oxidase 2 and Lactoperoxidase Expression in Intestinal Crypts and Species Differences May Limit Hydrogen Peroxide Scavenging During Mucosal Healing in Mice and Humans. (2017) (10)
Transcriptional profiles and stromal changes reveal bone marrow adaptation to early breast cancer in association with deregulated circulating microRNAs. (2019) (10)
Imatinib Spares cKit-Expressing Prostate Neuroendocrine Tumors, whereas Kills Seminal Vesicle Epithelial–Stromal Tumors by Targeting PDGFR-β (2016) (10)
T-8 Entecavir monotherapy in 418 NUC-naive patients with chronic hepatitis B from field practice: high efficacy and favorable safety profile over 3 years of treatment (2012) (10)
F.N.16 EFFECTIVENESS OF ENTECAVIR FOR NUC-NAIVE, HBeAg-NEGATIVE CHRONIC HEPATITIS B PATIENTS IN CLINICAL PRACTICE: A 2-YEAR MULTICENTER COHORT STUDY IN 311 PATIENTS (2010) (9)
CpG-Oligodeoxynucleotides activate tyrosinase-related protein 2–specific T lymphocytes but do not lead to a protective tumor-specific memory response (2004) (9)
Healthy and tumoral tissue resistivity in wild-type and sparc–/– animal models (2016) (9)
Perspectives for the gene therapy of malignant gliomas by suicide gene transfer. (1997) (9)
Sequence of human GAS3/PMP22 full-length cDNA. (1993) (9)
DNA vaccination against the ovarian carcinoma-associated antigen folate receptor alpha (FRalpha) induces cytotoxic T lymphocyte and antibody responses in mice. (1999) (9)
Carcinomas in Transgenic BALB / c Mice Carcinogenesis Than Transplantable p 185 More Effectively Inhibits DNA Vaccination Against Rat Her-2 / Neu Musiani and (2000) (8)
Frontline Science: Mast cells regulate neutrophil homeostasis by influencing macrophage clearance activity (2019) (8)
Low rates of genotypic resistance to adefovir in lamivudine resistant patients treated with adefovir-lamivudine combination therapy for 3 years (2006) (8)
Application of multicolor fluorescence in situ hybridization analysis for detection of cross-contamination and in vitro progression in commonly used murine tumor cell lines. (2002) (8)
Transarterial embolization with microspheres in the treatment of monofocal HCC. (2009) (8)
On OX40 and PD-1 Combination: Why Should OX40 Be First in Sequence? (2017) (8)
Antibody‐mediated blockade of JMJD6 interaction with collagen I exerts antifibrotic and antimetastatic activities (2017) (8)
Myeloid cell heterogeneity in lung cancer: implication for immunotherapy (2021) (7)
Safety and Efficacy of Directly Acting Antivirals in 2432 HCV Patients with Advanced Fibrosis: An Interim Analysis of the Lombardia Regional Network for Viral Hepatitis (2016) (7)
Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study (2019) (7)
P1119 EARLY VIRAL KINETICS DO NOT PREDICT TREATMENT OUTCOME WITH SOFOSBUVIR + RIBAVIRIN FOR 12 OR 24 WEEKS IN HCV GENOTYPE 2/3 PATIENTS IN THE VALENCE TRIAL (2014) (7)
14 A DRUG TRANSPORTER GENE POLYMORPHISM PREDICTS RENAL TUBULAR TOXICITY IN PATIENTS WITH CHRONIC HEPATITIS B ON LONG-TERM ADEFOVIR AND LAMIVUDINE COMBINATION (2010) (7)
CD 99 triggering induces methuosis of Ewing sarcoma cells through IGF-1 R / RAS / Rac 1 signaling (2018) (7)
P.04.7 A MORPHOMETRIC AND IMMUNOHISTOCHEMICAL STUDY TO ASSESS THE BENEFIT OF AN SVR IN HCV CIRRHOTIC PATIENTS (2012) (7)
Reciprocal influence of B cells and tumor macro and microenvironments in the ApcMin/+ model of colorectal cancer (2017) (7)
Expression of a growth arrest specific gene (gas‐6) during liver regeneration: Molecular mechanisms and signalling pathways (1994) (7)
696 ADD ON ADEFOVIR PREVENTS THE EMERGENCE OF ADV RESISTANCE IN LAMIVUDINE-RESISTANT PATIENTS: A 4-YEAR STUDY (2008) (7)
In vitro analysis of the melanoma/endothelium interaction increasing the release of soluble intercellular adhesion molecule 1 by endothelial cells (1999) (7)
Castration-Induced Downregulation of SPARC in Stromal Cells Drives Neuroendocrine Differentiation of Prostate Cancer (2021) (7)
Laser oncology in Italy: experimental research and clinical applications at the National Cancer Institute, Milan (1983) (7)
1009 EFFECTIVENESS OF ENTECAVIR FOR NUC-NAIVE, HBEAG-NEGATIVE CHRONIC HEPATITIS B PATIENTS IN CLINICAL PRACTICE: A 2-YEAR MULTICENTER COHORT STUDY IN 311 PATIENTS (2010) (7)
806 MANAGEMENT AND OUTCOMES OF ANEMIA IN THE INTERNATIONAL TELAPREVIR EARLY ACCESS PROGRAM, FOR PATIENTS WITH HEPATITIS C GENOTYPE 1 INFECTION (2013) (6)
Prevention by delay: nonspecific immunity elicited by IL-12 hinders Her-2/neu mammary carcinogenesis in transgenic mice. (2001) (6)
44 The long-term outcome of HBeAg-Negative patients with cirrhosis treated with lamivudine monotherapy: A 5-year prospective cohort study (2004) (6)
399 PNPLA3 I148M AFFECTS LIVER STEATOSIS IN PATIENTS WITH CHRONIC HEPATITIS B (2013) (6)
Adoptive immunotherapy of cancer with immune and activated lymphocytes: Experimental and clinical studies (1986) (6)
Adoptive immunotherapy of a BALB/c lymphoma by syngeneic anti-DBA/2 immune lymphoid cells: Characterization of the effector population and evidence for the role of the host's non-T cells (2004) (6)
Removal of the Treated Primary Tumor Metastatic-Induced Death after Surgical Mammary Tumor Growth and Prevents Encoding CC Chemokine Ligand 16 Inhibits Intralesional Injection of Adenovirus (2004) (6)
18 DRUG TRANSPORTER GENE POLYMORPHISM PREDICTS RENAL TUBULAR TOXICITY IN PATIENTS WITH CHRONIC HEPATITIS B ON LONG-TERM ADEFOVIR AND LAMIVUDINE COMBINATION (2010) (6)
Introduction: Cytokines and Cancer (2002) (6)
Fasting renders immunotherapy effective against low-immunogenic breast cancer while reducing side effects. (2022) (6)
Non-H-2 histocompatibility antigens encoded by Moloney-murine leukemia virus in Mov mouse strains are detectable by skin grafting and cytolytic T lymphocytes. (1988) (6)
Innovative Therapy, Monoclonal Antibodies and Beyond. (2017) (6)
Few, but Efficient: The Role of Mast Cells in Breast Cancer and Other Solid Tumors (2022) (6)
Ava I RFLP at the gas-1 locus on mouse chromosome 12. (1989) (6)
523 ADD-ON PEG-IFN IMPROVES HBSAG KINETICS IN PATIENTS LONG-TERM FULLY SUPPRESSED BY NUCLEOS(T)IDE ANALOGS (2012) (5)
SCD5-dependent inhibition of SPARC secretion hampers metastatic spreading and favors host immunity in a TNBC murine model (2022) (5)
Inheritance of a mutant histocompatibility gene and a new mammary tumor virus genome in the B6.KH-84 mouse strain (2004) (5)
Cytokine gene transfer in tumor cells as an approach to antitumor therapy (1992) (5)
Mechanisms for Tumor Killing and Use Fas / Fas Ligand-Independent CTL Clones Resist Fas Ligand-Induced Apoptosis + and CD 8 + Human Melanoma-Reactive CD 4 (1998) (5)
730 PEGBELIVER STUDY: HBSAG DECLINE AT WEEK 24 OF EXTENDED PEGINTERFERON ALFA-2A (PEG-IFNα-2A) THERAPY IS SIGNIFICANTLY ASSOCIATED WITH POST-TREATMENT RESPONSE IN HBEAG-NEGATIVE GENOTYPE D PATIENTS (2011) (5)
[496] SIX YEARS OF ON DEMAND LAM±ADV COMBINATION THERAPY SIGNIFICANTLY REDUCES THE DEVELOPMENT AND PROGRESSION OF ESOPHAGEAL VARICES IN PATIENTS WITH HBeAg-NEGATIVE CIRRHOSIS (2007) (5)
F-33 High prevalence of reduced bone mineral density in patients with chronic hepatitis B under nucleos(t)ides analogues treatment (2011) (5)
OC-13 ADVANCE study: Final results of the phase III trial with telaprevir in combination with PEG-IFN and RBV in treatment-naïve genotype 1 HCV (2011) (5)
Tumor cells engineered to produce cytokines or cofactors as cellular vaccines: Do animal studies really support clinical trials? (1995) (5)
P1032 LOW ACCURACY OF NON-INVASIVE TESTS FOR ASSESSING RESIDUAL CIRRHOSIS IN HEPATITIS C PATIENTS WITH A SUSTAINED VIROLOGICAL RESPONSE (2014) (5)
Tumor-cell-targeted cytokine gene therapy. (1991) (5)
Guidelines for the treatment of chronic viral hepatitis (1997) (5)
94 Prospective randomised trial on IFN-therapy for the secondary prevention of HCC recurrence after curative resection in HCV related cirrhosis. Preliminary report (2004) (5)
Retroviral heterogeneity in mouse lymphomas. (1988) (5)
Treatment of patients with chronic hepatitis C infection in Lombardia: a report by the Lombardia Hepatitis Network. (2016) (5)
Expression of a growth arrest specific gene (gas-1) in transformed cells. (1992) (5)
Repurposing of the Antiepileptic Drug Levetiracetam to Restrain Neuroendocrine Prostate Cancer and Inhibit Mast Cell Support to Adenocarcinoma (2021) (5)
Immunodominance in the T-cell response to multiple non-H-2 histocompatibility antigens. V. Chromosomal mapping of the immunodominant cytotoxic T-cell target-1 (CTT-1) (2004) (5)
Modulation of PD-1/PD-L1 axis in myeloid-derived suppressor cells by anti-cancer treatments. (2021) (5)
Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis (2021) (5)
777 INCIDENCE AND CLINICAL CONSEQUENCES OF REDUCED TUBULAR PHOSPHATE RE-ABSORPTION (TmPO4/GFR) IN NAÏVE CHRONIC HEPATITIS B PATIENTS TREATED WITH TENOFOVIR: A TWO-YEAR FIELD STUDY (2013) (4)
The ins and outs of osteopontin (2015) (4)
CIC-39Na reverses the thrombocytopenia that characterizes tubular aggregate myopathy (2022) (4)
Expression of H-2 and viral antigens and resistance to the antitumor lysis of tunicamycin-treated MBL-2 lymphoma cells. (1983) (4)
524 RESPONSE-GUIDED PEGINTERFERON ALFA-2A THERAPY BASED ON HBSAG LEVELS AT WEEK 12 AND WEEK 24 OR 48 IMPROVES RESPONSE RATES IN HBEAG-NEGATIVE, GENOTYPE D PATIENTS (2012) (4)
Macrophages Impair TLR9 Agonist Antitumor Activity through Interacting with the Anti-PD-1 Antibody Fc Domain (2021) (4)
[57] 3 YEARS OF ADEFOVIR AND LAMIVUDINE COMBINATION THERAPY MINIMIZES THE RISK OF GENOTYPIC RESISTANCE TO ADV IN LAM RESISTANT PATIENTS (2007) (4)
OC.09.6: GENETIC VARIATION IN IL28B POLYMORPHISM MAY PREDICT HBSAG CLEARANCE IN GENOTYPE D, HBEAG NEGATIVE PATIENTS TREATED WITH INTERFERON ALFA (2011) (4)
Ultrasound-guided intra-tumor injection of combined immunotherapy cures mice from orthotopic prostate cancer (2013) (4)
Deciphering the nonsense-mediated mRNA decay pathway to identify cancer cell vulnerabilities for effective cancer therapy (2021) (4)
OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis (2018) (4)
Intestinal Inflammation is Linked to Hypoacetylation of Histone 3 Lysine 27 and can be Reversed by Valproic Acid Treatment in Inflammatory Bowel Disease Patients (2020) (4)
Immunogenicity of a yeast‐recombinant hepatitis B vaccine in high‐risk children (1989) (4)
315 I148M PNPLA3 POLYMORPHISM IS ASSOCIATED WITH CLINICAL FEATURES IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (2012) (4)
CHANGES IN LIVER STIFFNESS DURING ENTECAVIR THERAPY IN PATIENTS WITH CHRONIC HEPATITIS B (2009) (4)
RORC 1 Regulates Tumor-Promoting ‘ ‘ Emergency ’ ’ Granulo-Monocytopoiesis Graphical Abstract Highlights (3)
1369 TRANSIENT ELASTOGRAPHY IN ACUTE ALCOHOLIC HEPATITIS AND DURING FOLLOW UP: A SINGLE-INSTITUTION EXPERIENCE (2012) (3)
Control of human melanoma growth in nude mice by autologous allo‐activated peripheral blood lymphocytes (1986) (3)
SPARC regulation of PMN clearance protects from pristane-induced lupus and rheumatoid arthritis (2020) (3)
Neutrophil extracellular traps arm DC vaccination against NPM-mutant myeloproliferation (2021) (3)
506 UNDETECTABLE HCV-RNA IN TELAPREVIR-TREATED PATIENTS: LOW CONCORDANCE BETWEEN TWO HIGHLY SENSITIVE REAL-TIME PCR ASSAYS (2013) (3)
OC-26 Treatment of hepatitis C genotype 1 patients with severe fibrosis or compensated cirrhosis: the Italian telaprevir early access program (2013) (3)
291 INSULIN RESISTANCE DOES NOT PREDICT A RESPONSE TO PEGYLATED INTERFERON PLUS RIBAVIRIN IN CHRONIC HEPATITIS C PATIENTS: A SUB-ANALYSIS OF THE MIST STUDY (2010) (3)
T-25 Impact of insulin resistance on antiviral efficacy of telaprevir-based regimen in treatment-naïve genotype 1 HCV: Results from C208 sub-analysis (2011) (3)
Treatment of a low immunogenic experimental tumour with alloactivated or tumour-immune lymphocytes. (1987) (3)
Chemoembolization with epirubicin drug-eluting beads (DEB-TACE) to treat early and intermediate hepatocellular carcinoma. (2010) (3)
The Italian Network for Tumor Biotherapy (NIBIT): Getting together to push the field forward (2008) (3)
Circulating miRNAs as Novel Non-Invasive Biomarkers to Aid the Early Diagnosis of Suspicious Breast Lesions for Which Biopsy Is Recommended (2021) (3)
Prospective validation of AASLD guidelines for the early diagnosis of hepatocellular carcinoma in cirrhotic patients (2008) (3)
Diagnostic value of Lens culinaris agglutinin isoform 3 fraction (AFP-L3%) and des-gamma-carboxy prothrombin (DCP) for the diagnosis of hepatocellular carcinoma in cirrhotic patients. (2010) (3)
Release of IFN-γ by acute myeloid leukemia cells remodels bone marrow immune microenvironment by inducing regulatory T cells. (2022) (3)
Circulating and tumor-associated neutrophil subtypes discriminate hyperprogressive disease (HPD) from conventional progression (PD) upon immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients (pts) and in vivo models. (2020) (3)
Is GPNMB the Achilles' Heel of Mo-MDSC While Marking Their Suppressive Activity? (2018) (3)
P1206 ITPA GENE VARIANTS AND ANEMIA DURING TELAPREVIR/PEGINTERFERON/RIBAVIRIN COMBINATION THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION (2014) (3)
382 CHANGES IN LIVER STIFFNESS DURING ENTECAVIR THERAPY IN PATIENTS WITH CHRONIC HEPATITIS B (2009) (3)
Strain polymorphism and tentative mapping of mouse ornithine decarboxylase. (1988) (2)
Genotype 3 infection in DAA era: Reports of a real life Northern Italy Network for viral hepatitis after 2 years by the start (2017) (2)
Progressive decline of HBsAg titers in longterm virological responders to nucleos(t)ide analogue therapy for chronic hepatitis B (2008) (2)
545 DECLINE OF BONE MINERAL DENSITY DURING LONG-TERM NUCLEOS(T)IDE ANALOG THERAPY: A LONGITUDINAL COHORT STUDY OF 135 PATIENTS WITH CHRONIC HEPATITIS B (2012) (2)
Low body mass index (BMI) predicts discordance between transient elastography (TE) and liver biopsy (LB) assessment of liver fibrosis (2007) (2)
Interferon-γ-Dependent Inflammatory Signature in Acute Myeloid Leukemia Cells Is Able to Shape Stromal and Immune Bone Marrow Microenvironment (2019) (2)
T-29 Early NK cell activation predicts successful treatment outcome in chronic HCV infection (2011) (2)
PROSPECTIVE STUDY OF DYSPLASTIC NODULES IN CIRRHOSIS: CORRELATION WITH CT VASCULAR PATTERN, HISTOLOGY AND DEVELOPMENT OF HEPATOCELLULAR CARCINOMA (2009) (2)
T-11 5-year entecavir in NUC-naïve, field-practice patients with CHB showed excellent viral suppression and safety but no prevention of HCC (2013) (2)
916 ENTECAVIR IS AN EFFECTIVE TREATMENT FOR NUC-NAIVE CHRONIC HEPATITIS B PATIENTS IN CLINICAL PRACTICE: 48-WEEK DATA FROM A LARGE MULTICENTER COHORT STUDY (2009) (2)
IMPORTANCE OF NON‐H‐2 GENES IN THE CONTROL OF THE IN VIVO GROWTH OF THE VIRUS INDUCED LYMPHOMA YC8 (1981) (2)
602 THE CANDIDATE HCV E1E2MF59 VACCINE IS SAFE IN CHRONIC HEPATITIS C PATIENTS AND ACCELLERATES THE SECOND PHASE VIRAL DECLINE UPON PRIMARY RESPONSE TO PEG-INTERFERON-2A/RIBAVIRIN THERAPY (2009) (2)
Tumor and dendritic cells as cellular vaccines: confrontation and perspectives – a symposium in writing (1998) (2)
934 DIFFERENCES IN HCV GENOTYPE 1 RVR RATES AMONG CLINICAL TRIALS IN EUROPE DEPEND ON HCV RNA ASSAY SENSITIVITY (2012) (2)
Treatment of hepatitis C genotype 1 patients with severe fibrosis or compensated cirrhosis: The german telaprevir early access program (2013) (2)
OC.03.2 ENTECAVIR FOR NUC-NAÏVE CHRONIC HEPATITIS B PATIENTS IN CLINICAL PRACTICE: LONG-TERM EFFECTIVENESS FROM A LARGE MULTICENTER COHORT STUDY IN 376 PATIENTS (2010) (2)
Oligodeoxynucleotides in Mice Antitumor Activity Induced by CpG Absence of the CD1 Molecule Up-Regulates (2002) (2)
Immune-tolerance to human iPS-derived neural progenitors xenografted into the immature cerebellum is overridden by species-specific differences in differentiation timing (2021) (2)
Successful treatment of hepatocellular carcinoma with transcatheter arterial embolization (TAE) with microspheres (Embosphere) (2006) (2)
P.1.29: A SUSTAINED VIROLOGICAL RESPONSE TO INTERFERON PREVENTS INSULIN RESISTANCE IN CHRONIC HEPATITIS C PATIENTS (2011) (2)
Conference on cancer vaccines (2000) (2)
Adjuvant adoptive immunotherapy with IL2 and lymphocytes from tumor-bearing mice: in vitro tumor-stimulated lymphocytes are more effective than LAK cells. (1991) (2)
Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC (2022) (2)
Presentation of tumor antigens. The role of dendritic cells (1999) (2)
O.064 Antiviral treatment for hepatitis C virus infection in the real practice: A nationwide Italian experience (the PROBE study) (2006) (2)
15 TELAPREVIR (TVR) q8h OR q12h COMBINED WITH EITHER PEGINTERFERON (PEG-IFN, P) ALFA-2A OR ALFA-2B AND RIBAVIRIN (RBV, R) IN TREATMENT-NAÏVE GENOTYPE 1 HEPATITIS C: FINAL RESULTS OF THE RANDOMIZED, OPEN-LABEL, MULTICENTER PHASE 2 STUDY C208 (2010) (2)
T Cells Expressing Receptor Recombination/Revision Machinery Are Detected in the Tumor Microenvironment and Expanded in Genomically Over-unstable Models (2021) (2)
Low probability of major liver related events in chronic hepatitis delta (2005) (2)
[566] PRE-TREATMENT FACTORS PREDICTING SUSTAINED VIROLOGICAL RESPONSE IN TREATMENT-NAIVE HCV GENOTYPE 1 PATIENTS PARTICIPATING IN A LARGE, PRACTICE-BASED NATIONWIDE OBSERVATIONAL STUDY (2007) (2)
Abstract 4480: Circulating and tumor associated neutrophil subtypes correlate with hyperprogressive disease (HPD) upon immunecheckpoint inhibitors (ICI) in advanced non-small cell lung cancer (aNSCLC) patients (pts) andin vivomodels (2020) (1)
753 NUCLEOS(T)IDE ANALOGUES CAN BE SAFELY DISCONTINUED IN CHRONIC HEPATITIS B PATIENTS ACHIEVING HBSAG SEROCLEARANCE (2011) (1)
Efficacy and safety of pegylated interferon plus ribavirin in patients with hepatitis C recurrence after liver transplantation: A single centre experience (2007) (1)
Adenosine Pathway in NSCLC With Molecular Drivers: Can Oncogene Addiction Translate Into Immune Addiction? (2022) (1)
P.03.3 TRANSIENT ELASTOGRAPHY IN CELIAC PATIENTS: A NON INVASIVE METHOD TO DETECT LIVER INVOLVEMENT ASSOCIATED TO CELIAC DISEASE (2012) (1)
Abstract A102: Osteopontin produced by myeloid cells determines the outcome of breast cancer metastases (2013) (1)
Multimodal and sequential treatment for hepatocellular carcinoma: How “real-life” complies with international recommendations (2018) (1)
F-05 Clinical implications of baseline population sequencing of the NS3 protease in HCV-1 partial or null-responders to Peg-interferon/ribavirin (2013) (1)
Progression through Multiple Oncogenic Mechanisms MicroRNA-221 /-222 Pathway Controls Melanoma − The Promyelocytic Leukemia Zinc Finger (2008) (1)
OC.03.3 INSULIN RESISTANCE DOES NOT PREDICT A RESPONSE TO PEGYLATED INTERFERON PLUS RIBAVIRIN IN CHRONIC HEPATITIS C PATIENTS: A SUB-ANALYSIS OF THE MIST STUDY (2010) (1)
Chronic hepatitis C (CH-C) genotype 1: An independent, multicenter RCT comparing PEG-IFN ALFA-2B 12KD plus ribavirin (RBV) and IFN ALFA-2B plus (RBV) in naive patients (2003) (1)
ACQUIRED DISEASES RESEARCH ARTICLE In vivo correction of genetic defects of monocyte/ macrophages using attenuated Salmonella as oral vectors for targeted gene delivery (2000) (1)
Intracellular osteopontin protects from autoimmunity-driven lymphoma development inhibiting TLR9-MYD88-STAT3 signaling (2022) (1)
Lymphocyte-Endothelial Cell Cross-Talk and Angiogenesis Depends on IL-12 Inhibition of Endothelial Cell Functions (2001) (1)
P.04.5 THE COURSE OF BONE MINERAL DENSITY IN PATIENTS WITH CHRONIC HEPATITIS B LONG TERM TREATED WITH NUCLEOS(T)IDE ANALOGS: A LONGITUDINAL COHORT STUDY (2012) (1)
Refined localization of H7 and Ctt1 on distal mouse chromosome 9 (2004) (1)
Abnormal expression of histocompatibility antigens on cancer cells. (1982) (1)
Circulating Fatty Acid Profile as a Biomarker for Immunotherapy in Advanced Non-Small Cell Lung Cancer. (2022) (1)
420 TRANSIENT ELASTOGRAPHY EARLY PREDICTS PROGRESSIVE RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION (2010) (1)
Up-Regulation of Immune Tolerance Genes in Leukemic Mesenchymal Stromal Cells Is Induced By Acute Myeloid Leukemia Cells through an IFN-Gamma-Dependent Inflammatory Signaling (2018) (1)
Safety of Simeprevir-Based Treatment for Hepatitis C in Real Practice: Preliminary Results from the Stily Observational Study (2016) (1)
794 PROSPECTIVE STUDY OF DYSPLASTIC NODULES IN CIRRHOSIS: CORRELATION WITH CT VASCULAR PATTERN, HISTOLOGY AND DEVELOPMENT OF HEPATOCELLULAR CARCINOMA (2009) (1)
389 LOW RISK OF HEPATOCELLULAR CARCINOMA RECURRENCE AFTER LIVER TRANSPLANTATION: A 3-YEAR FOLLOW-UP STUDY IN 78 PATIENTS WITH CHRONIC HEPATITIS B (2008) (1)
Goals and objectives of the Italian Network for Tumor Biotherapy (NIBIT). (2017) (1)
716 PROGNOSTIC GENE-EXPRESSION SIGNATURE FOR HEPATITIS C-RELATED EARLY-STAGE LIVER CIRRHOSIS (2012) (1)
Optimising management of patients with hepatitis C virus in the age of direct-acting antivirals: results of a Delphi consensus. (2018) (1)
769 GENOTYPE DEPENDENT PATTERN OF PEGINTERFERON ALFA-2B/RIBAVIRIN TREATMENT FAILURE IN HEPATITIS C VIRUS INFECTED PATIENTS WITH CIRRHOSIS: A SINGLE CENTER STUDY OF 471 NAIVE PATIENTS (2008) (1)
425 IL28B GENOTYPE IN HDV CHRONIC PATIENTS CORRELATES WITH UNFAVOURABLE OUTCOME BUT NOT WITH RESPONSE TO IFN TREATMENT (2013) (1)
912 PROGRESSIVE DECLINE OF HBsAg TITERS IN LONG- TERM VIROLOGICAL RESPONDERS TO NUCLEOS(T)IDE ANALOGUE THERAPY FOR CHRONIC HEPATITIS B (2009) (1)
OC-21 The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with an SVR (2012) (1)
Twenty-four months combination therapy with adefovir dipivoxil and lamivudine in lamivudine resistano patients with HBeAg-negative chronic hepatitis B (2005) (1)
CYTOKINE BASED TUMOR IMMUNOTHERAPY (1998) (1)
immune reactivity mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses Myeloid cell expansion elicited by the progression of spontaneous (2013) (1)
Abstract 2877: Dual role of mast cells in prostate tumors. (2013) (1)
F-35 Nucleos(t)ide analogues can be safely discontinued in chronic hepatitis B patients achieving HBsAg seroclearance (2011) (1)
Neutrophils discriminate between G-CSF producing and non-producing colon carcinoma cells: correlation with tumor inhibition (1991) (1)
CD40 Activity on Mesenchymal Cells Negatively Regulates OX40L to Maintain Bone Marrow Immune Homeostasis Under Stress Conditions (2021) (1)
Transduction of MHC-class I negative allogeneic cell line to improve the efficacy of anti-tumor vaccination. (2002) (1)
P1059 PORTAL HYPERTENSION BUT NOT HCC RISK IS ATTENUATED IN COMPENSATED CIRRHOTICS FOLLOWING 10 YEARS OF TREATMENT WITH NUCLEOS(T)IDE ANALOGS (2014) (1)
Antitumor Resistance Macrophages Inhibits M 1 Inflammatory Responses and B Overexpression in Tumor-Associated κ p 50 Nuclear Factor-Updated (2006) (1)
Regulatory T Cells in Cancer (2008) (1)
27 Rescue treatment with adefovir dipivoxil for lamivudine resistant patients pre- and post- liver transplantation (2003) (1)
Deciphering the nonsense-mediated mRNA decay pathway to identify cancer cell vulnerabilities for effective cancer therapy (2021) (1)
OX40 expression in tumor-associated Tregs as a potential prognostic biomarker and immunotherapeutic target in ovarian cancer. (2015) (1)
T-regulatory cells in Crohn's disease patients treated with infliximab (2008) (1)
722 LIVER STIFFNESS AND HEPATOCELLULAR CARCINOMA: IS IT REALLY USEFUL? (2013) (1)
OC-30 Incidence and clinical consequences of reduced tubular phosphate re-absorption in naïve CHB patients treated with tenofovir: a two-year field study (2013) (1)
High rates of tenofovir dose adjustments are required in Adefovir experienced patients with chronic hepatitis B: A 4-year prospective study in 320 patients (2014) (1)
Biased stroma in the autoimmunity-lymphoma transition (2013) (1)
259 DETERMINANTS OF BLEEDING FROM ESOPHAGEAL VARICES IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA TREATED WITH SORAFENIB (2013) (0)
Eradication of a disseminated BALB/c mice lymphoma by adoptive transfer of syngeneic anti-DBA/2 T lymphocytes does not require the partecipation of radiation-sensitive host cells (1985) (0)
Mechanisms of Tolerance Induction through T Regulatory Cells during Chemotherapy-Mediated Immunogenic Cell Death in Acute Myeloid Leukemia (2019) (0)
1148 THE PRESENCE OF HEPATITIS C VIRUS DELETION MUTANTS IN CHRONIC HEPATITIS C PATIENTS AND THEIR ROLE DURING PEG-IFN/RIBAVIRIN THERAPY IN HCV-1 PATIENTS (2011) (0)
ERYTHROID DIFFERENTIATION IS SUPPRESSED BY RIBAVIRIN DURING COMBINATION THERAPY WITH PEGYLATED INTERFERON-α2A IN CHRONIC HEPATITIS C: AN IN VITRO AND IN VIVO STUDY (2009) (0)
Isolation of differentially expressed genes related with ham saltino loss in Italian heavy pig (2005) (0)
P.09.14 FEASIBILITY AND REPRODUCIBILITY OF NON-INVASIVE LIVER AND PANCREATIC STIFFNESS ASSESSMENT IN A COHORT OF PATIENTS WITH ALCOHOL-RELATED LIVER DISEASE (2018) (0)
768 LOW RISK OF HEPATITIS B REACTIVATION IN PATIENTS WITH CHRONIC HEPATITIS C AND CONCURRENT INACTIVE HEPATITIS B INFECTION TREATED WITH INTERFERON AND RIBAVIRIN (2008) (0)
P.132 CHEMOEMBOLIZATION WITH EPIRUBICIN DRUG ELUTING BEADS TO TREAT EARLY AND INTERMEDIATE HEPATOCELLULAR CARCINOMA (2010) (0)
441 Hepatocellular carcinoma associated to chronic hepatitis delta (2004) (0)
OPTIMISING CANCER IMMUNOTHERAPY : CHALLENGES AND OPPORTUNITIES Summary of Presentations from a prIME Oncology Scientific Exchange on 21 st May 2016 in Amsterdam , Netherlands (2016) (0)
1647TiP Antiandrogen therapy and TMPRSS2 status: How prostate cancer patients are protected from COVID-19 pandemic (2021) (0)
[174] DETECTION OF AUTOANTIBODIES AGAINST CYTOCHROME P450 2E1 (CYP2E1) IN PATIENTS WITH RECURRENT HEPATITIS C (2007) (0)
Molecular and Cellular Pathobiology Inhibiting Interactions of Lysine Demethylase LSD 1 with Snail / Slug Blocks Cancer Cell Invasion (2012) (0)
P.1.317: ACUTE ALCOHOLIC HEPATITIS AND TRANSIENT ELASTOGRAPHY: OVERESTIMATION OF LIVER FIBROSIS RELATED TO LIVER CELL INFLAMMATION (2011) (0)
Abstract SY35-02: Bone marrow remodeling in response to distant tumor starts early in transformation (2019) (0)
OC-31 Low rates of SVR to peg-interferon plus ribavirin in HCV genotype 1 IL28B rs12979860 CC cirrhotic patients without rapid virological response (2012) (0)
169PNeoadjuvant eribulin following anthracycline and taxane in triple negative breast cancer (HOPE): A multicenter, two stage, phase II trial (2017) (0)
303 EARLY ACTIVATION OF EFFECTOR CYTOTOXIC NK CELLS PREDICTS SUCCESSFUL TREATMENT OUTCOME IN CHRONIC HCV INFECTION (2011) (0)
F-17 Serum HBsAg decline is faster than previously estimated in long-term NUC responders with low treatment-induced HBsAg levels (2013) (0)
Abstract 3526: The transcription factor ZEB1 shapes osteosarcoma aggressiveness by affecting tumor cell differentiation and stemness features (2023) (0)
Abstract 5506: Circulating immature neutrophils early detect hyperprogressive disease upon first-line PD-1/PD-L1 inhibitors in non-small cell lung cancer patients selecting best candidates for platinum-based chemotherapy and PD-1/PD-L1 inhibitors combinations (2023) (0)
Anti-IgE vaccination prevents human IgE-mediated severe anaphylaxis in humanized mice (2021) (0)
P1186 TREATMENT-NAIVE STABLE LIVER TRANSPLANT PATIENTS WITH GENOTYPE-1 HCV INFECTION: PHARMACOKINETIC RESULTS OF ADJUSTED DOSING WITH TACROLIMUS OR CYCLOSPORINE IN THE TELAPREVIR REPLACE STUDY (2014) (0)
Mesenchymal Transition o f High-Grade Breast CarcinomasDepends on Extracellular Matrix Control of Myeloid Suppressor Cell Activity Graphical (0)
251 Increased expression of vascular endothelial growth factor and its receptor in hepatocellular carcinoma and extra-tumoral cirrhotic tissues (2004) (0)
BBR 3576 a 9-aza-anthrapyrazole endowed with high antitumor activity on prostate carcinoma models (2007) (0)
15 First-line platinum-based chemotherapy combined with PD-1/PD-L1 inhibitors (ICI) prevents hyperprogression in non-small cell lung cancer (NSCLC) patients by reducing circulating immature neutrophils (2021) (0)
Oral CommunicationsA SEQUENTIAL PREDICTIVE ALGORITHM COMBINING APRI AND TRANSIENT ELASTOGRAPHY (TE) FOR DIAGNOSING LIVER FIBROSIS IN CHRONIC HEPATITIS C (2009) (0)
T-40 Clinical and economic impact of the updated AASLD criteria for the diagnosis of hepatocellular carcinoma (HCC) (2013) (0)
Snail / Slug-LSD 1 interaction inhibition and invasion arrest 1 Inhibiting interactions of lysine demethylase LSD 1 with Snail / Slug blocks cancer cell invasion Running Title : Inhibition of Snail / Slug-LSD 1 interaction and invasion (2012) (0)
T-41 Accuracy of [18F]fluorocholine (18F-FCH) PET/CT for the characterization of de novo liver nodules detected in cirrhotic patients: aprospective pilot study (2013) (0)
983 Steatosis is a cofactor for fibrosis and response to therapy in genotype 1B chronic hepatitis C (CHC) (2003) (0)
1065 COMBINED TRANSIENT ELASTOGRAPHY OF THE LIVER AND SPLEEN TO ASSESS DISEASE SEVERITY IN CHRONIC VIRAL LIVER DISEASE (2012) (0)
S28 T-regulatory cells in Crohn's disease patients treated with infliximab (2010) (0)
Lack of Improvement of Liver Stiffness during Sofosbuvir-Treatment in Decompensated Cirrhotic Patients Listed for Liver Transplant Seems to be Associated with more Severe Histological Damage in the Native Liver (2016) (0)
Abstract 1669: Immunometabolism of circulating neutrophils in hyperprogressive disease (HPD) upon first-line PD-1/PD-L1 inhibitors (ICI) alone or in combination with platinum-based chemotherapy (PCT) in non-small cell lung cancer (NSCLC) patients (pts) (2021) (0)
25P Platinum-based chemotherapy (PCT) addition to first-line PD-1/PD-L1 inhibitors (ICI) prevent hyperprogressive disease (HPD) in non-small cell lung cancer (NSCLC) patients (pts) by reducing circulating immature neutrophils (2022) (0)
Upon Adoptive Transfer Lymphocytes That Cure Lung Metastases Induces Immunoregulatory Type 2 CD 8 T IL-4-Transduced Tumor Cell Vaccine (1999) (0)
Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5–7, 2012 (2013) (0)
P.103 No evidence for ADV resistance in HBeAg-negative lamivudine resistant patients treated with lamivudine-adefovir combination for 3 years (2006) (0)
Diagnostic accuracy and standardization of fine needle biopsy in the characterization of liver nodules in cirrhosis. (2010) (0)
2013 POSTER Bone marrow-derived TNF-a promotes tumour growth in a spontaneous model of mammary carcinogenesis (2007) (0)
MA04.06 PD-1 Blockade Promotes Hyperprogressive Disease in NSCLC Through Macrophages Activation via Antibody-Fc/FcR Interaction (2018) (0)
IgG 2 a Induced by Interleukin ( IL ) 12-producing Tumor Cell Vaccines but not IgGl Induced by IL-4 Vaccine Is Associated with the Eradication of Experimental MÃ © tastases 1 (2006) (0)
Extra-hepatic tumor recurrence after directly-acting-antiviral (DAA) therapy in HCV patients (2019) (0)
OC-9 The presence of hepatitis C virus deletion mutants in chronic hepatitis C patients and their role during PEG-IFN/ribavirin therapy (2011) (0)
F-08 IL28B genotype is not associated with insulin resistance in chronic hepatitis C patients (2013) (0)
F-13 Switching to tenofovir is safe in most CHB patients with a reduced glomerular filtration rate due to previous exposure to adefovir dipivoxil (2013) (0)
Transient elastography (TE) detects graft damage in liver transplanted (LT) patients with aetiologies other than HCV (2008) (0)
1072 A five-year cohort study of patients with dual infection with HBV and HCV (2003) (0)
Immune-tolerance to human iPS-derived neural progenitors xenografted into the immature cerebellum is overridden by species-specific differences in differentiation timing (2021) (0)
Contributes to Mammary Carcinogenesis Production of Tumor Necrosis Factor That Critically Oncogene-Driven Intrinsic Inflammation Induces Leukocyte (2010) (0)
31 Salivary glands impairment during interferon/ribavirin treatment in patients with chronic hepatitis C (2003) (0)
cIAP1 regulates the EGFR/Snai2 axis in triple-negative breast cancer cells (2018) (0)
P.18.16 HEPATIC AND SPLENIC STIFFNESS MEASURED BY TRANSIENT ELASTOGRAPHY: FEASIBILITY AND POSSIBLE ROLE IN PATIENTS WITH HEMOGLOBINOPATHIES (2013) (0)
Leukemic Transformation Induces the Constitutive Expression of Indoleamine 2,3-Dyoxigenase Which Directly Increases CD4+CD25+ T Regulatory Cells. (2005) (0)
T-17 Sustained virologic response to interferon prevents the lethal consequence of clinical decompensation in patients who develop a hepatocellular carcinoma post antiviral-treatment (2012) (0)
477 High rates of hepatitis B virus reverse seroconversion in anti-HBc carriers undergoing allogeneic bone marrow transplantation (2006) (0)
Constitutive expression of HOXB7 causes stem cell proliferation and myeloid-restricted differentiation (1997) (0)
JMJD6 shapes a pro-tumor microenvironment via ANXA1-dependent macrophage polarization in breast cancer. (2023) (0)
The Role of Cytokines in Antitumor Immune Response: From Detection to Gene Therapy (1993) (0)
Precursors to Enhance Antigen Uptake and Targets Immature Dendritic Cell Tumor Cell Killing Induces Th1 Cytokines Heat Shock Protein 70 Induced During (1999) (0)
P.04.10 THE ROLE OF HEPATIC AND SPLEEN STIFFNESS IN THE ASSESSMENT OF DISEASE SEVERITY IN CHRONIC VIRAL HEPATITIS (2012) (0)
P992 FIRST-LINE TREATMENT OF 90 CONSECUTIVE HCC WITH DRUG ELUTING BEADS CHEMOEMBOLIZATION (DEB-TACE) (2014) (0)
In vitro detection of cell-mediated immunity to individual tumor-specific antigens of methylcholanthrene induced balb/c fibrosarcomas. Abstr. (1983) (0)
Abstract 2556: The protective role of mast cells against neuroendocrine prostate cancer depends on the release of cytokines mediated by intracellular osteopontin (2022) (0)
P965 PERSONALIZED THERAPY WITH SORAFENIB FOR HEPATOCELLULAR CARCINOMA (2014) (0)
1008 SUSTAINED VIROLOGIC RESPONSE TO INTERFERON PREVENTS THE LETHAL CONSEQUENCE OF CLINICAL DECOMPENSATION IN PATIENTS WHO DEVELOP A HEPATOCELLULAR CARCINOMA POST ANTIVIRAL-TREATMENT (2012) (0)
Serum nuclear autoantibodies with nucleolar pattern in chronic liver diseases (2006) (0)
Genotype 3 infection in DAA era: Preliminary reports of a real life northern Italy network for viral hepatitis (2016) (0)
P1035 LIVER (LS) AND SPLEEN STIFFNESS (SS) IN PATIENTS WITH HAEMOGLOBINOPATHIES. DATA FROM TRANSIENT ELASTOGRAPHY (TE) (2014) (0)
T-46 Determinants of bleeding from esophageal varices in patients with advanced hepatocellular carcinoma treated with sorafenib (2013) (0)
OC-31 The outcome of chronic hepatitis D is predicted by the levels of HDV viremia (2013) (0)
PF576 NONSENSE-MEDIATED MRNA DECAY IS A THERAPEUTIC TARGET IN MULTIPLE MYELOMA (2019) (0)
Increased Plasma Levels of Von Willebrand Factor and Factor VIII (FVIII) During Acute Bacterial Infection Drive a Pro-Hemostatic Imbalance and Herald Severe Outcome in Cirrhosis (2016) (0)
T-08 Interplay between on-treatment predictors and donor/recipients IL28B in predicting SVR to pegIFN/ribavirin in HCV-1,4 liver transplant recipients (2013) (0)
Abstract 2141: Stromal SPARC deficiency skews prostate cancer toward neuroendocrine differentiation (2018) (0)
Interferon (cid:103) –independent Rejection of Interleukin 12–transduced Carcinoma Cells Requires CD4 (cid:49) T Cells and Granulocyte/Macrophage Colony–stimulating Factor (1998) (0)
OC.03.6 FIELD PRACTICE WITH SORAFENIB IN ADVANCED HCC: EFFECTIVENESS CONFIRMED, TOLERABILITY REDUCED BUT USUALLY MANAGEABLE, COMPARED TO REGISTRATION TRIALS (2010) (0)
Immunizing potential of cytokine-transduced tumor cells. (2000) (0)
MEF2C and SOCS2 in stemness regulation (2015) (0)
Chemotherapy-Dependent ATP Release from Leukemia Dying Cells Induces Indoleamine 2,3-Dioxygenase 1 in Dendritic Cells (2016) (0)
O123 POST SORAFENIB SURVIVAL IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA: THE ROLE OF TUMOR PROGRESSION AND LIVER IMPAIRMENT (2014) (0)
426 SERUM LEVELS OF HBsAg AND HBVDNA ARE NOT ASSOCIATED TO CLINICAL OUTCOME IN PATIENTS WITH CHRONIC HDV INFECTION (2013) (0)
Carcinomas in Transgenic BALB/c Mice Carcinogenesis Than Transplantable p185 More Effectively Inhibits DNA Vaccination Against Rat Her-2/Neu (2000) (0)
Minimal increases of alpha-fetoprotein above the normal value strongly predict HCC development in compensated Caucasian HBV cirrhotics treated by entecavir or tenofovir: a 7-year longitudinal cohort study in 225 patients (2017) (0)
Effect of the PNPLA3 I148M polymorphism on the outcome of peg-interferon plus ribavirintreatment in chronic hepatitis C (2011) (0)
When Failure Is Worse Than Giving Up: The Case of CTL. (2019) (0)
LYMPHOID NEOPLASIA Bone marrow stroma CD40 expression correlates with in ﬂ ammatory mast cell in ﬁ ltration and disease progression in splenic marginal zone lymphoma (2014) (0)
Role of PD-L1 expression in triple-negative breast cancer stem cells. (2018) (0)
Cancer immunity and immunotherapy beyond COVID-19 (2023) (0)
P.134 DIAGNOSTIC YIELD AND STANDARDIZATION OF FINE NEEDLE BIOPSY IN THE CHARACTERIZATION OF LIVER NODULES IN CIRRHOTIC PATIENTS (2010) (0)
F-9 The I148M PNPLA3 polymorphism is associated with the clinical presentation and prognosis of hepatocellular carcinoma (2012) (0)
Alloimmunization-induced syngeneic antitumor immunity in balb/c mice. Abstr. (1982) (0)
B7.1 PROVIDES A STRONG COSTIMULATORY SIGNAL FOR AUTOLOGOUS T-CELLS IN RECOGNIZING HUMAN OVARIAN CANCER CELLS (1997) (0)
110 No recurrence in patients transplanted for YMDD genotypic mutations using pre-emptive lamivudine followed by combination prophylaxis (2004) (0)
Cancer bio-immunotherapy XVIII annual NIBIT-(Italian network for tumor biotherapy) meeting, October 15–16, 2020 (2022) (0)
Is Treg plasticity the Achilles’ heel to their functional inactivation? (2011) (0)
Accuracy of the Radiological Diagnosis of Hepatocellular Carcinoma outside the Periodic Surveillance with Ultrasound (2016) (0)
Active immunization of melanoma patients with IL-2-OR IL-4-transduced allogeneic melanoma cells (1997) (0)
997 Active immunization of melanoma patients with IL-2-transfected allogeneic melanoma cells. A phase I-II study (1995) (0)
P586 APPEARANCE OF COMBINED HEPATOCELLULAR CHOLANGIOCARCINOMA IN CIRRHOSIS AT CONTRAST ENHANCED IMAGING TECHNIQUES (2014) (0)
Editors' viewpoint - Response (2014) (0)
Abstract B157: OX40 expression in tumor-associated Tregs as a potential prognostic biomarker and immunotherapeutic target in ovarian cancer (2016) (0)
Overview of the synergistic use of radiotherapy and immunotherapy in cancer treatment: current challenges and scopes of improvement (2023) (0)
Eighth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, October 7–9, 2010 (2011) (0)
Multimodal and sequential treatmente for hepatocellular carcinoma: how “real-life” complies with international recommendations (2018) (0)
Polygenic control of the in vivo immunity to balb/c sarcomas and lymphomas. Abstr. (1980) (0)
283 INDEPENDENT PREDICTORS OF DISCORDANCE BETWEEN TRANSIENT ELASTOGRAPHY (TE) AND LIVER BIOPSY (LB) (2008) (0)
1099 ITPA VARIANTS PREDICT TREATMENT-INDUCED ANEMIA AND THE NEED FOR RIBAVIRIN DOSE REDUCTION AND ERYTHROPOIETIN SUPPORT (2012) (0)
Transduction of protectin (CD59) enhances the resistance of human melanomas to homologous CDC (1998) (0)
The natural history of hepatic macroregenerative nodules developing in cirrhotic patients during surveillance with ultrasound. (2010) (0)
ITPA deficiency does not predict anaemia during Ribavirin containing DAA all oral regimens for HCV (2016) (0)
Microenvironment and Immunology Osteopontin Shapes Immunosuppression in the Metastatic Niche (2014) (0)
588 DIAGNOSTIC VALUE OF LENS CULINARIS AGGLUTININ ISOFORM 3 (AFP-L3) AND DES-GAMMA-CARBOXY PROTHROMBIN (DCP) FOR THE DIAGNOSIS OF HCC IN CIRRHOTIC PATIENTS (2010) (0)
Genetic Unresponsiveness to a Murine Fibrosarcoma Determined by the Host Genetic Environment but not by Lymphocyte Precursor Genotype (1985) (0)
Sixth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, 16–18 October 2008 (2009) (0)
Serum Markers for early diagnosis of hepatocellular carcinoma in hepatitis C cirrhotic patients with sustained virological response to direct-acting antivirals treatment (2017) (0)
Comparison of field practice to registration trials of sorafenib in advanced HCC for effectiveness and tolerability. (2010) (0)
CS3.3 INDEPENDENT PREDICTORS OF DISCORDANCE BETWEEN TRANSIENT ELASTOGRAPHY (TE) AND LIVER BIOPSY (2008) (0)
810 INTERPLAY BETWEEN ON-TREATMENT PREDICTORS AND DONOR/RECIPIENT (D/R) IL28B STATUS IN PREDICTING SUSTAINED VIROLOGICAL RESPONSE (SVR) IN HCV-1,4 LIVER TRANSPLANT (LT) RECIPIENTS TREATED WITH PEG-INTERFERON+ RIBAVIRIN (PR) (2013) (0)
P.051 Hepatitis B virus reverse seroconversion in allogeneic hematopoietic stem cell transplantation (2006) (0)
OC-1 Prospective Italian multicenter field-practice study with sorafenib for advanced hepatocellular carcinoma (2011) (0)
Core Antigen Quantification to Monitor Treatment Efficacy in Patients with Chronic Hepatitis C Receiving Directly Acting Antivirals (2016) (0)
Abstract A24: Bone marrow hematopoietic adaptation as a sensor of early, pre-invasive, epithelial malignancy (2018) (0)
ATF3 Reprograms the Bone Marrow Niche in Response to Early Breast Cancer Transformation (2022) (0)
Serum autoantibodies correlates with severity of hepatitis C recurrence after liver transplant (2006) (0)
PA.103 LOW RISK OF HEPATITIS B REACTIVATION IN PATIENTS WITH CHRONIC HEPATITIS C AND CONCURRENT INACTIVE HEPATITIS B INFECTION TREATED WITH INTERFERON AND RIBAVIRIN (2008) (0)
187 INDEPENDENT INFLUENCERS OF TRANSIENT ELASTOGRAPHY ASSESSMENT OF LIVER FIBROSIS IN HEPATITIS B AND HEPATITIS C PATIENTS (2009) (0)
Gene expression profile at week 2 of neoadjuvant therapy course predicts outcome in HER2-positive breast cancer patients: an explorative analysis from NeoALTTO (2022) (0)
448 Rescue treatment with adefovir dipivoxil in lamivudine resistant patients with chronic hepatitis B (2004) (0)
Bitter taste receptor genes in pigs: SNP identification by using next- generation semiconductor sequencing (2013) (0)
1057P Baseline circulating immature neutrophils anticipate hyperprogressive disease (HPD) upon 1st-line PD-1/PD-L1 inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients (pts) and are reduced by platinum-based chemotherapy (PCT) and ICI combinations (2022) (0)
Competent B Cells - Differentiation of IL-10 Mast Cells Control the Expansion and (2014) (0)
975 Salivary glands impairment in patients with chronic hepatitis C undergoing PEG-interferon/ribavirin treatment (2003) (0)
High rates of renal tubular damage in HBV monoinfected patients long-term treated with Tenofovir: a cross-sectional, single center, real-life study in 414 patients (2017) (0)
Ninth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, Italy, October 19–22, 2011: New perspectives in the immunotherapy of cancer (2012) (0)
Modulation of antigen presenting cells-tumor cells interactions (1999) (0)
The Induction of Inhibitory Pathways in Dendritic Cells May Hamper the Efficient Activation of Anti-Leukemia T Cells within Chemotherapy-Induced Immunogenic Cell Death (2015) (0)
Interleukin-12 Gene Expression into Acute Myeloid Leukemia-Derived Dendritic Cells Overcomes T-Cell Functional Impairment Induced by Leukemic Microenvironment. (2004) (0)
PA.102 VERY EARLY ADD-ON ADEFOVIR THERAPY IN PATIENTS WITH SUB-OPTIMAL VIROLOGICAL RESPONSE TO LAMIVUDINE (2008) (0)
Low diagnostic accuracy of the AASLD radiologic criteria for hepatocellular carcinoma in grade I tumors. (2010) (0)
T-17 Add-on Peg-IFN improves HBsAg kinetics in HBeAg-negative patients long-term fully suppressed by nucleos(t)ide analogs (2013) (0)
CS.2.4 CONTRAST IMAGING TECHNIQUES CORRELATE WITH TUMOR GRADING IN THE DIAGNOSIS OF HEPATOCELLULAR CARCINOMA IN CIRRHOTIC PATIENTS UNDER SURVEILLANCE (2010) (0)
Mast cells and immune response in cancer (2014) (0)
P744 DEPDC5 GENE LOCUS ASSOCIATES WITH SEVERE LIVER FIBROSIS IN INDIVIDUALS WITH CHRONIC HCV INFECTION (2014) (0)
Perspectives in Cancer Research Immunoprevention of Cancer : Is the Time Ripe ? 1 (2000) (0)
Cancer bio-immunotherapy XVI annual NIBIT-(Italian Network for Tumor Biotherapy) meeting, October 11–13 2018, Milan, Italy (2020) (0)
Inosine Triphosphatase Deficiency does not Predict Anaemia during Ribavirin Containing DAA All Oral Regimens for HCV (2016) (0)
190 GRAFT DYSFUNCTION (GD) IN HBV RECURRENCEFREE RECIPIENTS IS ASSOCIATED WITH SERUM AUTOANTIBODIES REACTIVITY (2008) (0)
Genotypic analysis of YMDD locus of HBV in patients responding to lamivudine monotherapy (2003) (0)
A TaqI RFLP at the gas-2 locus. (1989) (0)
OC-7 NK profiles of non-responder and relapser patients with cHCV infection treated with SOC (2012) (0)
Interferon g – independent Rejection of Interleukin 12 – transduced Carcinoma Cells Requires CD 4 1 T Cells and Granulocyte / Macrophage Colony – stimulating Factor (2010) (0)
PA.106 HEPATITIS C VIRUS GENOTYPES AND PATTERNS OF PEGINTERFERON ALFA-2B/RIBAVIRIN TREATMENT FAILURE IN PATIENTS WITH CIRRHOSIS: A SINGLE CENTER STUDY OF 471 NAÏVE PATIENTS (2008) (0)
P1212 USE OF BASELINE FIBROSCAN TO PREDICT EFFICACY AND SAFETY OF TREATMENT FOR 1143 PATIENTS IN THE TELAPREVIR EARLY ACCESS PROGRAMME (2014) (0)
Healthy and tumoral tissue resistivity in wild-type and sparc–/– animal models (2016) (0)
594 ERYTHROID DIFFERENTIATION IS SUPPRESSED BY RIBAVIRIN DURING COMBINATION THERAPY WITH PEGYLATED INTERFERON-α2a IN CHRONIC HEPATITIS C: AN IN VITRO AND IN VIVO STUDY (2009) (0)
Regulation and effect of TNFβ expression in melanoma cell lines: 283 (1993) (0)
P187 INNATE ANTIVIRAL RESPONSES IN HBeAg NEGATIVE PATIENTS WITH CHRONIC HEPATITIS B (CH-B) UNDER LONG-TERM NUCLEOS(T)IDE ANALOGUE (NUC) TREATMENT: IMPLICATIONS FOR FUTURE IMMUNE THERAPIES (2014) (0)
F-5 Prospective validation of 2010 AASLD guideline for the diagnosis of 1-2 cm HCC in cirrhotic patients (2012) (0)
Serum antinuclear antibodies (ANA) in HCV-related cirrhosis: Correlation with liver cell proliferation status and hepatocellular carcinoma (HCC) development (2006) (0)
448 IL28B GENOTYPE IS NOT ASSOCIATED WITH INSULIN RESISTANCE IN CHRONIC HEPATITIS C PATIENTS (2013) (0)
229 NATURAL HISTORY AND MULTIMODALITY TREATMENT OF EARLY HEPATOCELLULAR CARCINOMA PROSPECTIVELY DETECTED IN CIRRHOTIC PATIENTS UNDER SURVEILLANCE (2010) (0)
P.133 DIAGNOSTIC VALUE OF LENS CULINARIS AGGLUTININ ISOFORM 3 FRACTION (AFP-L3%) AND DES-GAMMA-CARBOXY PROTHROMBIN (DCP) FOR THE DIAGNOSIS OF HCC IN CIRRHOTIC PATIENTS (2010) (0)
Notch pathway promotes multiple myeloma cell IL-6 independence (2014) (0)
Acute and Late Mast Cell Responses The Aryl Hydrocarbon Receptor Modulates (2012) (0)
Author response for "IL‐10‐producing B cells are characterized by a specific methylation signature" (2019) (0)
P.162 TRANSIENT ELASTOGRAPHY EARLY PREDICTS PROGRESSIVE RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION (2010) (0)
Search of candidate genes for salting loss of ham by using Fluoro Differential Display (FDD) (2005) (0)
Evaluation of osteonectin as a marker of the osteoblastic lineage in bone tumors (1991) (0)
Evaluating liver fibrosis in chronic hepatitis c (CHC), accuracy of two new predictive models (2006) (0)
OC3.04.6 LIVER CELL PROLIFERATION AND LIVER CANCER RISK IN PATIENTS WITH HEPATITIS C VIRUS-RELATED CIRRHOSIS UNDER ANTIVIRAL TREATMENT (2008) (0)
P271 INTERACTION BETWEEN DIETARY FACTORS AND INSULIN RESISTANCE IN THE PATHOGENESIS OF NONALCOHOLIC STEATOHEPATITIS (2014) (0)
1080 LOW RATES OF SVR TO PEGINTERFERON PLUS RIBAVIRIN IN HCV GENOTYPE 1 IL28B RS12979860 CC CIRRHOTIC PATIENTS WITHOUT RAPID VIROLOGICAL RESPONSE (2012) (0)
Role of the carbohydrate prosthetic groups in the biosynthesis of membrane antigens and in the H-2-restricted lysis of MBL-2 lymphoma cells. (1983) (0)
T-16 Contrast-enhanced CT scan differentiates hepatocellular carcinoma and intrahepatic cholangiocarcinoma in cirrhosis (2012) (0)
Ly-5.185 molecule is associated with thymic maturation of lymphocytes but not with their cytotoxic activity. (1987) (0)
P.1.95: DUAL CUT-OFF ELASTOGRAPHY TO ASSESS LIVER FIBROSIS IN CHRONIC HEPATITIS B: A COHORT STUDY WITH INTERNAL VALIDATION (2011) (0)
Abstracts selected for oral presentation: EMBRN webinar March 3rd 2021 1 1 Inotodiol ameliorates Th2 mediated airway inflammation by attenuating mast cell activities in a mouse model of asthma (2021) (0)
F-36 Transarterial chemoembolization with drug-eluting beads (DEB TACE) for BCLC-A hepatocellular carcinoma (HCC): a radical option? (2013) (0)
35 Preclinical model for gene therapy: Role of the host (1995) (0)
TM6SF2, MBOAT7 and PNPLA3 genotypes in patients with untreated HCV chronic hepatitis and alcohol intake (2017) (0)
P658 LOW RISK OF HEPATITIS B VIRUS REACTIVATION IN HBsAg NEGATIVE, ANTI-HBc POSITIVE CARRIERS UNDERGOING RITUXIMAB FOR RHEUMATOID ARTHRITIS (2014) (0)
46 IMMUNOLOGICAL PROFILES OF NON-RESPONDER AND RELAPSER PATIENTS WITH CHRONIC HCV INFECTION TREATED WITH STANDARD OF CARE THERAPY (2012) (0)
35 THE NATURAL HISTORY OF HEPATIC MACROREGENERATIVE NODULES DEVELOPING IN CIRRHOTIC PATIENTS DURING SURVEILLANCE WITH ULTRASOUND (US) (2010) (0)
P991 CHEMOEMBOLIZATION OF HEPATOCELLULAR CARCINOMA WITH M1 DRUG ELUTING BEADS: SAFETY AND EFFECTIVENESS (2014) (0)
1066 LIVER STIFFNESS IN A SERIES OF CELIAC PATIENTS (2012) (0)
HEPATOCELLULAR CARCINOMA ASSOCIATED TO CHRONIC HEPATITIS DELTA (2009) (0)
This information is current as Host T Cell Antitumor Response Requires CD40-Apc Signaling to Boost the Vaccine Synergizes with GM-CSF and OX40 Ligand-Transduced Tumor Cell (2013) (0)
Cytokine gene-transduced tumor cells in cancer therapy: Tumor inhibition by non-specific and specific immune mechanisms (1993) (0)
Liver, Pancreas and Biliary Tract N association of HLA-haplotypes with primary sclerosing q cholangitis (PSC) in a southern European population (2003) (0)
117 PROSPECTIVE STUDY OF NK CELL PHENOTYPE IN RECURRENT HCV INFECTION AFTER LIVER TRANSPLANT (2008) (0)
T-18 Liver follicular helper T-cells in chronic hepatitis C (2011) (0)
P.140 NATURAL HISTORY AND MULTIMODALITY TREATMENT OF EARLY HEPATOCELLULAR CARCINOMA PROSPECTIVELY DETECTED IN CIRRHOTIC PATIENTS UNDER SURVEILLANCE (2010) (0)
Bystander secretion of hsp70 provides adjuvant effect throughout DC-NK interaction (2005) (0)
Natural history and multimodality treatment of early hepatocellular carcinoma prospectively detected in cirrhotic patients under surveillance. (2010) (0)
Prognostic role of CD73 in metastatic non small cell lung cancer according to the presence of driver alterations (2019) (0)
P33.01 Circulating Extracellular Vesicles as Biomarkers for Immune-Checkpoint Inhibitors in Advanced NSCLC (2021) (0)
Temporal trends of access to DAAs treatments for HCV in the Navigatore-Lombardia network: Evolution of AIFA criteria, DAA regimens and patient features (2018) (0)
Cancer bio-immunotherapy XVII annual NIBIT (Italian Network for Tumor Biotherapy) meeting, October 11–13 2019, Verona, Italy (2021) (0)
Moloney murine leukemia virus encodes a non h 2 histocompatibility antigen in viremic mov strains (1988) (0)
Impact of von Willebrand factor/ADAMTS-13 on the pro-coagulant imbalance detected in cirrhosis (2017) (0)
Intra-tumor heterogeneity of Diffuse Large B-cell Lymphoma involves the induction of diversified stroma-tumor interfaces (2020) (0)
Serum autoantibodies against cytochrome P450 2E1 (CYP2E1) predict severity of liver graft hepatitis C recurrence (2007) (0)
194 THE NATURAL HISTORY OF HEPATIC MACROREGENERATIVE NODULES DEVELOPING IN CIRRHOTIC PATIENTS DURING SURVEILLANCE WITH ULTRASOUND (2010) (0)
587 DIAGNOSTIC YIELD AND STANDARDIZATION OF FINE NEEDLE BIOPSY IN THE CHARACTERIZATION OF LIVER NODULES IN CIRRHOTIC PATIENTS (2010) (0)
746 PROSPECTIVE VALIDATION OF 2010 AASLD GUIDELINE FOR THE DIAGNOSIS OF 1-2 CM HCC IN CIRRHOTIC PATIENTS (2012) (0)
T-31 Effect of the PNPLA3 I148M polymorphism on the outcome of peg-interferon plus ribavirin treatment in chronic hepatitis C (2012) (0)
P1210 PREDICTORS OF SVR24 FOR 1078 PATIENTS WITH SEVERE FIBROSIS OR COMPENSATED CIRRHOSIS: THE INTERNATIONAL TELAPREVIR ACCESS PROGRAM (2014) (0)
Changes of AFP and PIVKA-II levels during DAA treatment and their predictive value for early diagnosis of HCC in HCV cirrhotic patients with SVR to DAA treatment (2018) (0)
Seventh annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, 1–3 October 2009 (2010) (0)
F-12 IL28B genotype in patients with chronic hepatitis delta (HDV) correlates with unfavourable outcome but not with response to IFN treatment (2013) (0)
Abstract 4054: Mast cells contribute to T cell tolerance against prostate cancer- associated antigens favoring tumor growth (2015) (0)
Transient elastography (TE) is an accurate tool in monitoring liver-transplanted (LT) patients with recurrent hepatitis C (2007) (0)
Survival and risk factors associated with severe fibrosis in patients with recurrent hepatitis C (HepC-R) (2008) (0)
Diagnostic role of circulating extracellular matrix-related proteins in non-small cell lung cancer (2018) (0)
20 Liver expression of estrogen receptors alpha and beta correlates with aetiology and presentation of hepatocellular carcinoma (2003) (0)
T.N.38 SAFETY AND EFFICACY OF PEG-IFN/RBV THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C AND HIGH TITRES OF SERUM AUTOANTIBODIES: A SUB-ANALYSIS OF THE MIST STUDY (2010) (0)
P.11.16 LIVER STIFFNESS AND HEPATOCELLULAR CARCINOMA: A SINGLE-CENTRE EXPERIENCE (2013) (0)
Macrophage Infiltration in Tumor Stroma Myeloid-Derived Suppressor Cell Expansion and the Tumor-Bone Marrow Axis Responsible for Mediated MMP-9 Inhibition Breaks − Amino-Biphosphonate (2007) (0)
T-36 Fibrosis progression in patients with chronic hepatitis C is not influenced by IL28B polymorphisms (2011) (0)
myb That Express c-Oligodeoxynucleotides in Colon Adenocarcinoma Cell Lines Antisense myb Inhibition of Proliferation by c-Updated Version (2006) (0)
T-37 Distribution of the IL28B rs12979860 polymorphism and its influence on sustained virological response rates in the MIST trial (2011) (0)
P.15.15 Transient Elastography in Acute Alcoholic Hepatitis: Overestimation of the Fibrosis Due to Inflammation (2012) (0)
CD40 provides immune privilege to the bone marrow hematopoietic niche (2020) (0)
PC.01.1 MANAGEMENT OF BILIARY ANASTOMOTIC STRICTURE AFTER LIVER TRANSPLANTATION (BASALT STUDY): RESULTS OF A NATIONAL SURVEY IN ITALY (2016) (0)
Hepatitis Delta prevalence and clinical expression in an immigrant population in Italy (2015) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Mario Paolo Colombo?

Mario Paolo Colombo is affiliated with the following schools:

Mario Paolo Colombo's Academic­Influence.com Rankings

Mario Paolo Colombo's Degrees

Similar Degrees You Can Earn

Why Is Mario Paolo Colombo Influential?

Mario Paolo Colombo's Published Works

Published Works

What Schools Are Affiliated With Mario Paolo Colombo?

Mario Paolo Colombo's AcademicInfluence.com Rankings